Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 31, 2024 (filed on Apr 02, 2024)Insider Name:Stratton John GOwnership Type:Direct OwnershipSecurities:Stock Equivalent UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:323Price:$113.66
-
Mar 31, 2024 (filed on Apr 02, 2024)Insider Name:Roman Michael FOwnership Type:Direct OwnershipSecurities:Stock Equivalent UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:310Price:$113.66
-
Mar 31, 2024 (filed on Apr 02, 2024)Insider Name:Gonzalez Patricia PaolaOwnership Type:Direct OwnershipSecurities:Stock Equivalent UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:290Price:$113.66
-
Mar 31, 2024 (filed on Apr 02, 2024)Insider Name:Alpern Robert JOwnership Type:Direct OwnershipSecurities:Stock Equivalent UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:69Price:$113.66
-
Mar 01, 2024 (filed on Mar 04, 2024)Insider Name:Salvadori Daniel Gesua SiveOwnership Type:Direct OwnershipSecurities:Common shares without par valueNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-963Price:$118.50
-
Mar 01, 2024 (filed on Mar 04, 2024)Insider Name:Morrone Louis H.Ownership Type:Direct OwnershipSecurities:Common shares without par valueNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-801Price:$118.50
-
Mar 01, 2024 (filed on Mar 04, 2024)Insider Name:Moreland Mary KOwnership Type:Direct OwnershipSecurities:Common shares without par valueNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-676Price:$118.50
-
Mar 01, 2024 (filed on Mar 04, 2024)Insider Name:Mccoy John A. Jr.Ownership Type:Direct OwnershipSecurities:Common shares without par valueNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-472Price:$118.50
-
Mar 01, 2024 (filed on Mar 04, 2024)Insider Name:Earnhardt Lisa DOwnership Type:Direct OwnershipSecurities:Common shares without par valueNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-694Price:$118.50
-
Mar 01, 2024 (filed on Mar 04, 2024)Insider Name:Allen Hubert LOwnership Type:Direct OwnershipSecurities:Common shares without par valueNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-853Price:$118.50
Filings by filing date
-
Mar 31, 2024 (filed on Apr 02, 2024)Insider Name:Stratton John GOwnership Type:Direct OwnershipSecurities:Stock Equivalent UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:323Price:$113.66
-
Mar 31, 2024 (filed on Apr 02, 2024)Insider Name:Roman Michael FOwnership Type:Direct OwnershipSecurities:Stock Equivalent UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:310Price:$113.66
-
Mar 31, 2024 (filed on Apr 02, 2024)Insider Name:Gonzalez Patricia PaolaOwnership Type:Direct OwnershipSecurities:Stock Equivalent UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:290Price:$113.66
-
Mar 31, 2024 (filed on Apr 02, 2024)Insider Name:Alpern Robert JOwnership Type:Direct OwnershipSecurities:Stock Equivalent UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:69Price:$113.66
-
Feb 29, 2024 (filed on Mar 04, 2024)Insider Name:Wainer Andrea FOwnership Type:Direct OwnershipSecurities:Common shares without par valueNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-8,339Price:$120.05
-
Mar 01, 2024 (filed on Mar 04, 2024)Insider Name:Salvadori Daniel Gesua SiveOwnership Type:Direct OwnershipSecurities:Common shares without par valueNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-963Price:$118.50
-
Feb 29, 2024 (filed on Mar 04, 2024)Insider Name:Salvadori Daniel Gesua SiveOwnership Type:Direct OwnershipSecurities:Common shares without par valueNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-8,874Price:$120.05
-
Mar 01, 2024 (filed on Mar 04, 2024)Insider Name:Morrone Louis H.Ownership Type:Direct OwnershipSecurities:Common shares without par valueNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-801Price:$118.50
-
Feb 29, 2024 (filed on Mar 04, 2024)Insider Name:Morrone Louis H.Ownership Type:Direct OwnershipSecurities:Common shares without par valueNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-3,455Price:$120.05
-
Mar 01, 2024 (filed on Mar 04, 2024)Insider Name:Moreland Mary KOwnership Type:Direct OwnershipSecurities:Common shares without par valueNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-676Price:$118.50
News
Biz Brief
Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 100 Abbott Park Road, Abbot Park ABBOTT PARK IL 60064-3500 |
Tel: | N/A |
Website: | https://www.abbott.com |
IR: | See website |
Key People | ||
Robert B. Ford Chairman of the Board, Chief Executive Officer | Randel W. Woodgrift Senior Vice President - Cardio Rhythm Management | Philip P. Boudreau Chief Financial Officer, Senior Vice President - Finance |
Robert E. Funck Executive Vice President - Finance | Hubert L. Allen Executive Vice President, General Counsel, Secretary | Mary K. Moreland Executive Vice President - Human Resources |
Lisa D. Earnhardt Executive Vice President, Group President - Medical Devices | Louis H. Morrone Executive Vice President - Core Diagnostics | Daniel Gesua Sive Salvadori Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products | Andrea Wainer Executive Vice President - Rapid and Molecular Diagnostics |
Business Overview |
Abbott Laboratories is a global healthcare company. The Company is engaged in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. The Diagnostic Products segment is engaged in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment is involved in the worldwide sales of a broad line of adult and pediatric nutritional products. The Medical Devices segment includes the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation, and diabetes care products. |
Financial Overview |
For the three months ended 31 March 2024, Abbott Laboratories revenues increased 2% to $9.96B. Net income decreased 7% to $1.23B. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income was offset by Selling, general and administrative - Ba increase of 6% to $2.93B (expense). Dividend per share increased from $0.51 to $0.55. |
Employees: | 114,000 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | N/A |
Annual revenue (TTM): | $40,326M as of Mar 31, 2024 |
EBITDA (TTM): | $9,592M as of Mar 31, 2024 |
Net annual income (TTM): | $5,630M as of Mar 31, 2024 |
Free cash flow (TTM): | N/A |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 1,735,184,289 as of Feb 28, 2024 |
Index Membership: | S&P 500 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |